AbbVie is preparing to put full Phase 3 data behind one of the more consequential additions to its oncology pipeline after etentamig produced a 74% objective response rate and reduced the risk of disease progression or death by 60% against investigator-selected standard therapies in triple-class-exposed relapsed or refractory multiple myeloma. The detailed CERVINO results are scheduled for a plenary presentation at the International Myeloma Society meeting in Glasgow on September 25, giving clinicians their first complete view of whether AbbVie’s second-generation BCMA-directed bispecific can combine strong efficacy with a treatment schedule practical enough for broader outpatient use.
The topline results already establish a meaningful efficacy difference. Among 393 patients who had received a median three previous lines of therapy, 74.0% responded to etentamig compared with 45.7% receiving standard available therapy. Progression-free survival produced a hazard ratio of 0.40, equivalent to a 60% reduction in the relative risk of progression or death, while the benefit appeared across all prespecified subgroups evaluated by AbbVie.
The overall survival picture is encouraging but not yet definitive. Twelve-month survival was 87.9% with etentamig against 72.0% in the comparator group, producing a hazard ratio of 0.48, but the prespecified efficacy boundary for overall survival had not been crossed at the interim cutoff. That distinction matters because the data support a favorable survival trend without yet establishing the formal overall survival conclusion that a mature analysis could eventually provide.
Why could etentamig be commercially different from another active myeloma bispecific?
Multiple myeloma has become one of the clearest demonstrations that efficacy alone does not determine commercial adoption. BCMA-directed CAR-T therapies and bispecific antibodies have produced deep responses in patients with heavily treated disease, but cytokine release syndrome, infections, neurological events, step-up dosing and monitoring requirements can complicate use outside specialized centers.
AbbVie designed etentamig around that practical problem. The investigational BCMA x CD3 bispecific uses a low-affinity CD3-binding domain intended to moderate immune activation, a bivalent BCMA-binding component designed to maintain tumor targeting, and retained FcRn binding that supports monthly dosing after a single step-up dose. AbbVie cautions that the proposed structural relationships have not been fully established clinically, but CERVINO provides the first large Phase 3 test of whether the design translates into a differentiated treatment experience.
Among patients receiving the single step-up regimen, cytokine release syndrome occurred in 28.3%, with most events graded as mild and no Grade 3 or higher events reported. One patient experienced Grade 1 immune effector cell-associated neurotoxicity syndrome, while no Grade 2 or higher cases were reported. Treatment discontinuation because of adverse events occurred in 3.6% of etentamig patients compared with 9.6% receiving standard therapy.
That does not make the safety profile trivial. Grade 3 or 4 infections occurred in 27.7% of etentamig recipients versus 19.2% in the comparator arm, demonstrating that infection remains a substantial issue with T-cell-redirection therapy. Fatal infections were numerically lower with etentamig, at 1.5% compared with 3.1%, but clinicians will need the complete dataset to understand infection duration, immunoglobulin effects, prophylaxis and how risks change with prolonged exposure.
Why does monthly dosing matter so much for community myeloma treatment?
Treatment frequency becomes commercially meaningful when therapies are used for long periods. Monthly dosing after one step-up dose could reduce the number of hospital and clinic visits compared with regimens requiring more frequent administration, particularly if the safety profile allows treatment to migrate beyond major academic centers.
That matters because the pool of patients who could benefit from bispecific antibodies is considerably larger than the number actually treated at specialist cellular-therapy centers. CAR-T therapy requires manufacturing, specialized facilities and extensive logistical coordination. Off-the-shelf bispecific antibodies remove some of those barriers, but complex initiation and monitoring can still concentrate treatment in tertiary institutions.
AbbVie explicitly sees outpatient and community-based care as part of etentamig’s potential differentiation. If the full CERVINO data persuade physicians that the initial safety-management burden is relatively manageable, the therapy could address one of the most important remaining access constraints in BCMA treatment.
The economics extend beyond convenience. Community administration can widen the addressable prescriber base, increase eligible patient volume and reduce the risk that patients deteriorate before reaching a specialized treatment center. In heavily pretreated multiple myeloma, where disease can progress rapidly, ease of access can become part of clinical effectiveness in the real world.
How meaningful is a 74% response rate in triple-class-exposed disease?
The CERVINO population had already been exposed to three major myeloma treatment categories: proteasome inhibitors, immunomodulatory drugs and anti-CD38 monoclonal antibodies. At that stage, patients commonly face increasingly resistant disease and fewer broadly effective treatment options.
Etentamig therefore was not tested against untreated or easy-to-treat disease. Investigator-selected comparators included carfilzomib plus dexamethasone, elotuzumab plus pomalidomide and dexamethasone, or selinexor plus bortezomib and dexamethasone. The substantial response-rate difference against those active treatment choices strengthens the relevance of the Phase 3 result.
Response rate is nevertheless only part of the commercial story. Myeloma therapies can produce impressive initial tumor reductions but differ materially in how long responses last. Progression-free survival therefore adds important evidence, and the hazard ratio of 0.40 suggests the benefit extends beyond simply producing more early responses.
The September 25 presentation should provide greater detail on depth of response, measurable residual disease, duration of response and subgroup performance. Those measures will help determine whether etentamig can compete effectively with existing BCMA-targeted options rather than merely join an increasingly crowded treatment category.
Why does AbbVie need a stronger oncology growth engine?
AbbVie entered the post-Humira period with unusually successful diversification in immunology and neuroscience. Second-quarter 2026 net revenue increased 10.2% to $16.99 billion, while Skyrizi generated $5.51 billion and Rinvoq produced $2.53 billion. Humira revenue, by contrast, fell almost 36% to $756 million as biosimilar competition continued eroding the former blockbuster.
Oncology remains smaller than those growth engines, which makes pipeline productivity strategically important. AbbVie said its broader oncology portfolio includes more than 35 investigational medicines across blood cancers and solid tumors, and the company is using multiple mechanisms including antibody-drug conjugates, multispecific antibodies, small molecules and CAR-T approaches.
At the International Myeloma Society meeting, etentamig will appear alongside ABBV-2001, a CD38 x BCMA x CD3 trispecific T-cell engager, and surzetoclax, a BCL-2 inhibitor. That means AbbVie is not simply trying to commercialize one late-line bispecific. It is building several potentially complementary assets that could eventually be sequenced or combined across different myeloma populations.
What is current investor sentiment around AbbVie’s Phase 3 pipeline?
AbbVie shares have been trading near their 52-week high, with recent market data placing the stock around $262 to $263. The shares had gained roughly 24% over the preceding year, suggesting investors have continued rewarding strong Skyrizi and Rinvoq execution while assigning increasing value to newer pipeline opportunities.
Etentamig is unlikely to determine AbbVie’s valuation on its own because the current earnings base remains dominated by larger franchises. The significance is more about reducing concentration risk. Every credible late-stage oncology asset makes AbbVie slightly less dependent on sustaining exceptional growth from its two dominant immunology products.
The CERVINO result is particularly useful because it contains both an efficacy signal and a potential delivery advantage. If full data confirm meaningful depth and durability of response alongside a manageable initiation process, physicians may have a reason to choose etentamig beyond another BCMA label.
What should PDN watch when the full CERVINO results are presented?
The first question is response depth. Complete response rates, measurable residual disease negativity and duration of response will help establish whether the 74% overall response rate translates into clinically durable disease control.
The second is infection management. Grade 3 and 4 infections were more common with etentamig than standard therapy, so additional information about prophylaxis, immunoglobulin replacement, hospitalization and exposure duration will matter greatly for community use.
The third is overall survival maturity. The 12-month survival difference is encouraging, but AbbVie correctly noted that the statistical boundary had not been crossed. A future significant survival result would make the regulatory and commercial case substantially stronger.
AbbVie plans to discuss CERVINO with regulators after the Phase 3 success. The larger question is whether the company has developed not merely another effective BCMA bispecific but one that can move this powerful treatment class farther from specialized centers and closer to routine myeloma practice.
